Literature DB >> 24157938

High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease.

M Degerman Gunnarsson1, L Lannfelt, M Ingelsson, H Basun, L Kilander.   

Abstract

OBJECTIVE: Cerebrospinal fluid (CSF) amyloid β42 (Aβ42), total tau (t-tau) and phosphorylated tau (p-tau) are useful as predictors of conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia. However, results are contradictory as to whether these biomarkers reflect the future rate of clinical decline.
METHODS: This is a retrospective study on 196 patients with AD [mild/moderate AD (n = 72) or AD-MCI (n = 124) at baseline] with a follow-up period of 2-9 years' duration (median 6 years). Lumbar punctures were performed at baseline as a part of the diagnostic procedure.
RESULTS: We found an increased risk of rapid cognitive decline defined as a drop in the Mini-Mental State Examination score of ≥ 4 points/year in patients with CSF t-tau concentrations above the median (OR 3.31, 95% CI 1.53-7.16) and CSF p-tau above the median (OR 2.53, 95% CI 1.21-5.26). Patients with CSF t-tau in the highest quartile had a higher risk of dying in severe dementia (HR 4.67, 95% CI 1.16-18.82).
CONCLUSIONS: In this large AD cohort, we found an association between high levels of CSF t-tau and p-tau and a more aggressive course of the disease, measured as a rapid cognitive decline and a higher risk of dying in severe dementia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24157938     DOI: 10.1159/000355556

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  13 in total

1.  The β-amyloid peptide compromises Reelin signaling in Alzheimer's disease.

Authors:  Inmaculada Cuchillo-Ibañez; Trinidad Mata-Balaguer; Valeria Balmaceda; Juan José Arranz; Johannes Nimpf; Javier Sáez-Valero
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

2.  Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.

Authors:  Panagiotis Alexopoulos; Lukas Werle; Jennifer Roesler; Nathalie Thierjung; Lena Sophie Gleixner; Igor Yakushev; Nikolaos Laskaris; Stefan Wagenpfeil; Philippos Gourzis; Alexander Kurz; Robert Perneczky
Journal:  Alzheimers Res Ther       Date:  2016-12-09       Impact factor: 6.982

3.  Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting.

Authors:  Malene Schjønning Nielsen; Anja Hviid Simonsen; Volkert Siersma; Steen Gregers Hasselbalch; Peter Høgh
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-10-07

4.  CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease.

Authors:  Adla Boumenir; Emmanuel Cognat; Severine Sabia; Claire Hourregue; Matthieu Lilamand; Aline Dugravot; Elodie Bouaziz-Amar; Jean-Louis Laplanche; Jacques Hugon; Archana Singh-Manoux; Claire Paquet; Julien Dumurgier
Journal:  Alzheimers Res Ther       Date:  2019-03-28       Impact factor: 6.982

Review 5.  Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches.

Authors:  Douglas Galasko
Journal:  Front Neurol       Date:  2015-12-16       Impact factor: 4.003

6.  High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease.

Authors:  Malin Degerman Gunnarsson; Martin Ingelsson; Kaj Blennow; Hans Basun; Lars Lannfelt; Lena Kilander
Journal:  Alzheimers Res Ther       Date:  2016-06-06       Impact factor: 6.982

Review 7.  Disease modification and Neuroprotection in neurodegenerative disorders.

Authors:  Jeffrey Cummings
Journal:  Transl Neurodegener       Date:  2017-09-26       Impact factor: 8.014

8.  Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease.

Authors:  Hanneke F M Rhodius-Meester; Hilkka Liedes; Ted Koene; Afina W Lemstra; Charlotte E Teunissen; Frederik Barkhof; Philip Scheltens; Mark van Gils; Jyrki Lötjönen; Wiesje M van der Flier
Journal:  Alzheimers Res Ther       Date:  2018-02-20       Impact factor: 6.982

9.  Plasma tau predicts cerebral vulnerability in aging.

Authors:  Jose L Cantero; Mercedes Atienza; Jaime Ramos-Cejudo; Silvia Fossati; Thomas Wisniewski; Ricardo S Osorio
Journal:  Aging (Albany NY)       Date:  2020-11-04       Impact factor: 5.682

10.  Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.

Authors:  Christoph Mueller; Christeena John; Gayan Perera; Dag Aarsland; Clive Ballard; Robert Stewart
Journal:  Eur J Epidemiol       Date:  2020-05-15       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.